The strategic shift will allow the firm to focus on advancing a newly announced in vivo gene-editing therapy candidate that's in preclinical development.
NEW YORK – Cancer Research UK and Australian charity the Minderoo Foundation said on Wednesday they are collectively committing approximately £3.4 million (about $4.4 million) to fund an adaptive ...
The companies will study genetic associations linked to autoimmune diseases to identify target genes as well as patients most likely to respond to therapy.
Avacta will tap into Tempus' real-world data and machine learning abilities to develop drugs with its fibroblast activation protein (FAP)-based platform.